Probatebeta
Drug

TG100-801

As of the edition of 20 October 2026, TG100-801 is a small molecule: stopped in 2008; acts on BLK, EPHB4 and FGFR1 and 13 more.

Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.

The drug

Status
Stopped, 2008
Kind
Small molecule
Registered trials
2, 1 stopped early
Disease areas
Eye; Heart and blood vessels; Hormones

US protection

No US approval on record.

With no US approval on record there are no listed US patents or exclusivities.

This is the US only.

Companies that need a new molecule because of this drug

16 company-target rows on route A because of this drug.

Companies on route A for this drug

In the product

16 company-target rows are on route A because of TG100-801.

See the 16 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.

Targets

GeneProteinUniProt
LCKTyrosine-protein kinase LckP06239
FYNTyrosine-protein kinase FynP06241
YES1Tyrosine-protein kinase YesP07947
LYNTyrosine-protein kinase LynP07948
HCKTyrosine-protein kinase HCKP08631
PDGFRBPlatelet-derived growth factor receptor betaP09619
FGRTyrosine-protein kinase FgrP09769
FGFR1Fibroblast growth factor receptor 1P11362
SRCProto-oncogene tyrosine-protein kinase SrcP12931
FLT1Vascular endothelial growth factor receptor 1P17948
FGFR2Fibroblast growth factor receptor 2P21802
KDRVascular endothelial growth factor receptor 2P35968
FRKTyrosine-protein kinase FRKP42685
BLKTyrosine-protein kinase BlkP51451
EPHB4Ephrin type-B receptor 4P54760
SRMSTyrosine-protein kinase SrmsQ9H3Y6

Registered trials

PhaseTrialsCompletedActiveStopped early
Phase 11100
Phase 21001
All trials2

Who ran its trials

CompanyRoleYears
TargeGenLead sponsor of trials2006 to now

Other drugs at LCK

All of LCK